Advertisement


Alexander E. Perl, MD, on Acute Myeloid Leukemia: Treatment Updates

NCCN 2021 Virtual Annual Conference

Advertisement

Alexander E. Perl, MD, of the Abramson Cancer Center at the University of Pennsylvania, discusses the major changes in 2021 to the NCCN Clinical Practice Guidelines in Oncology for managing acute myeloid leukemia, including venetoclax plus azacitidine, a new standard of care in patients ineligible for intensive induction; oral azacitidine maintenance in fit patients unable to complete intensive consolidation chemotherapy or proceed to transplant; and an increased focus on minimal residual disease status post-induction.



Related Videos

Leukemia
Lymphoma

Jennifer R. Brown, MD, PhD, on Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors and their second-generation counterparts, the need for ways to manage disease progression on novel drugs, and minimal residual disease as a predictor of response.

Bladder Cancer
Immunotherapy

Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the changing therapeutic landscape in which atezolizumab, avelumab, and pembrolizumab have either been approved or are under review for treating urothelial bladder cancer in the metastatic, superficial, and adjuvant settings.

Prostate Cancer

Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer

Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging techniques; PET tracers to help better detect, diagnose, and treat disease; PARP inhibitors for BRCA and other mutations; and new sequencing of drugs.

COVID-19

Thomas K. Varghese, Jr, MD, on the Effects of the COVID-19 Pandemic on Cancer Care

Thomas K. Varghese, Jr, MD, of Huntsman Cancer Institute at the University of Utah, summarizes a panel discussion on how the COVID-19 pandemic has interrupted cancer screenings, when telemedicine works and when it doesn’t, opening alternative care sites in the community, and the emotional and mental toll the coronavirus has taken on health-care providers.

Issues in Oncology

Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers

Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vaccination rates, thus lowering the rate of cervical, genital, and head/neck cancers, all of which are linked to HPV.

Advertisement

Advertisement



Advertisement